Repurposed leukemia drug tested as new hope for Tough-to-Treat lung cancer
NCT ID NCT06225427
Summary
This early-stage study is testing a drug called gilteritinib in patients with advanced, ALK-positive non-small cell lung cancer that has stopped responding to other targeted treatments. The main goals are to find the safest dose and understand the side effects. Researchers are studying this drug, which is already approved for a type of leukemia, because lab tests suggest it might work against lung cancer cells that have become resistant to current therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
NOT_YET_RECRUITINGLos Angeles, California, 90048, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Georgetown University
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.